Inhibrx Biosciences
INBX
93.36
-0.05
-0.05%
Inhibrx Biosciences
US · INBX
#3022 by market cap
Listed 2024
93.36
-0.05
-0.05%
Live - 5344 symbols - heartbeat 108s ago
· 2026-10-08 07:55
Pre-market
91.50
-1.99%
After-hours
93.41
+0.05%
- Market cap
- 1.37B
- P/E (TTM)i
- -10.51
- P/Bi
- -25.93
- EPSi
- -9.04
- Div yieldi
- 0.00%
- 52W posi
- 51%
Reader sentiment
Are you bullish or bearish on INBX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 9.0 percentage points.
Institutional ownership
- Held by institutions
- 99.53% -9.00pp
- Institutions
- 198 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund32.71%
Hedge Fund25.65%
Public Company25.61%
Individual/Insider15.56%
VC/PE Fund10.88%
Government Pension Fund2.98%
Private Company0.91%
Sovereign Wealth Fund0.62%
Family Office/Trust0.18%
Top holders as of 2026-06-30
Viking Global Investors LP
9.40% · 1.38M sh
Morgan Stanley
8.87% · 1.31M sh
Perceptive Advisors LLC
8.82% · 1.30M sh
Sanofi
7.87% · 1.16M sh
John Kayyem
7.30% · 1.07M sh
Mark Lappe
6.53% · 960.41K sh
HighTower Advisors, LLC
5.92% · 870.55K sh
Bank of America Corporation
5.72% · 841.14K sh
BlackRock
5.61% · 825.97K sh
Schonfeld Strategic Advisors LLC
4.74% · 697.59K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
27 filings tracked · 0 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| John Kayyem | Independent Director | 7.30% |
| Mark Lappe | Chairperson & CEO | 6.53% |
| Douglas Forsyth | Independent Director | 1.54% |
| Kristiina Vuori | Independent Director | 0.14% |
| Kimberly Manhard | Independent Director | 0.05% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2024-05-29 | Douglas Forsyth | Independent Director | Sale to Issuer | -598,257 | $30.00 |
| 2024-05-29 | Douglas Forsyth | Independent Director | Derivative Sale to Issuer | -62,259 | -- |
| 2024-05-29 | Kimberly Manhard | Independent Director | Derivative Sale to Issuer | -65,759 | -- |
| 2024-05-29 | John Kayyem | Independent Director | Sale to Issuer | -3,274,301 | $30.00 |
| 2024-05-29 | John Kayyem | Independent Director | Derivative Sale to Issuer | -62,259 | -- |
| 2024-05-29 | Mark Lappe | Chairperson & CEO | Sale to Issuer | -3,045,654 | $30.00 |
| 2024-05-29 | Mark Lappe | Chairperson & CEO | Derivative Sale to Issuer | -245,000 | -- |
| 2024-05-29 | Kristiina Vuori | Independent Director | Derivative Sale to Issuer | -60,000 | -- |
| 2024-05-29 | Brendan Eckelman | Founder & Chief Scientific Officer | Sale to Issuer | -2,055,553 | $30.00 |
| 2024-05-29 | Brendan Eckelman | Founder & Chief Scientific Officer | Derivative Sale to Issuer | -33,334 | -- |
| 2024-05-29 | Kelly Deck | Chief Financial Officer | Derivative Sale to Issuer | -45,000 | -- |
| 2024-05-27 | Brendan Eckelman | Founder & Chief Scientific Officer | Open Market Disposition | -300,000 | $34.30 |
| 2024-05-21 | Brendan Eckelman | Founder & Chief Scientific Officer | Other Derivative Disposition | -5,010 | $23.30–33.63 |
| 2024-05-05 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -19,711 | $34.24 |
| 2024-03-25 | Kelly Deck | Chief Financial Officer | Other Derivative Disposition | -2,896 | $10.52–34.16 |
| 2024-03-21 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -110 | $35.00 |
| 2024-03-20 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -3,113 | $35.09 |
| 2024-03-19 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -16,777 | $35.02 |
| 2024-03-12 | Brendan Eckelman | Founder & Chief Scientific Officer | Other Derivative Disposition | -1,898 | $33.63 |
| 2024-03-12 | Kelly Deck | Chief Financial Officer | Other Derivative Disposition | -32,431 | $11.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:55:24 · For reference only, not investment advice and not tailored to your situation.